JNJ-79635322

Phase 1, First-in-Human, Dose Escalation Study of JNJ-79635322, a Trispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated AL Amyloidosis

Near Add Your Location

Sorting 9 by

City of Hope Comprehensive Cancer Center
Beckman Research Institute
Duarte, CA
  • Accepting patients
Mount Sinai Hospital
Tisch Cancer Institute
New York, NY
  • Accepting patients
Colorado Blood Cancer Institute
Sarah Cannon at Presbyterian/St. Luke's Medical Center (HealthONE)
Denver, CO
  • Accepting patients
Abramson Cancer Center - University of Pennsylvania (UPENN)
University of Pennsylvania
Philadelphia, PA
  • Accepting patients
MD Anderson Cancer Center
The University of Texas
Houston, TX
  • Accepting patients
UCSF Helen Diller Comprehensive Cancer Center
University of California San Francisco
San Francisco, CA
  • Accepting patients
1,365 hidden based on your filters. Show All

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.